Brief: Cingulate Completes Pre-NDA Meeting With FDA To Discuss New Drug Application For Lead ADHD Asset CTX-1301
Brief: Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301
Brief: Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301
Brief: Cingulate CEO Shane Schaffer Was Charged With One Count Of "Aggravated Domestic Battery"
Brief: Cingulate Files For Resale Of Up To 1.5 Million Shares By The Selling Stockholder - SEC Filing
Brief: Cingulate Announces Adjournment Of Special Meeting
Brief: Cingulate Inc Files For Common Stock Offering Of Up To $2.9 Million - SEC Filing
U.S. STOCKS ON THE MOVE-Boeing, AST SpaceMobile, Syndax
Cingulate rises after receiving European patent for ADHD drug
Brief: Cingulate Achieves Key Manufacturing Milestone In The Development Of Its Adhd Drug CTx-1301 In Preparation For FDA Marketing Clearance
Brief: FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
Brief: Cingulate Files Prospectus Related To Offer, Resale Of 2 Mln Shares
Brief: Cingulate Promotes Controller Jennifer Callahan To Chief Financial Officer
U.S. STOCKS ON THE MOVE-China ADR, Hess Corp, Cingulate
Brief: Cingulate Says Got Guidance From U.S. FDA Regarding Clinical Program For Ctx-1301
Cingulate shares surge in after the bell trading
Brief: Cingulate's Louis Van Horn Retired from CFO Role Effective Immediately
U.S. RESEARCH ROUNDUP- Cigna Group, Datadog, Landstar System
Brief: Cingulate Receives Guidance From FDA On Path Forward For Anxiety Asset Ctx-2103 (Buspirone)